Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (9): 859-866.doi: 10.3969/j.issn.1000-6621.2021.09.002

• 指南·规范·共识 • 上一篇    下一篇

耐药肺结核全口服化学治疗方案中国专家共识(2021年版)

首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会   

  • 收稿日期:2021-07-28 出版日期:2021-09-10 发布日期:2021-09-07
  • 基金资助:
    基于结核病专病队列和生物样本的大数据平台关键技术研究(平台2021-2);“十三五”国家重大新药创制项目(2017ZX09304009)

Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition)

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis   

  • Received:2021-07-28 Online:2021-09-10 Published:2021-09-07

摘要:

2020年世界卫生组织(World Health Organization,WHO)提出了针对耐药肺结核的全口服化学治疗方案。分析显示,与接受含注射剂治疗方案组相比,使用全口服治疗方案可获得较高的治疗成功率。尽管WHO指南中推荐了针对不同耐药人群的全口服化学治疗方案,但有些药物品种或使用剂量并不适合我国患者,目前尚无针对我国耐药肺结核患者的全口服化学治疗方案的共识。为制定符合我国实际情况的耐药肺结核全口服化学治疗方案,中国防痨协会联合首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所和《中国防痨杂志》编辑委员会共同组织专家撰写了《耐药肺结核全口服化学治疗方案中国专家共识(2021年版)》(简称“共识”)。本共识根据近年来国内外耐药肺结核全口服化学治疗方案的研究进展,推荐了适用于我国耐药肺结核患者的全口服化学治疗方案,包括使用药物种类、剂量,以及适用患者类型及其应用和排除标准;同时,对治疗过程中可能遇到的相关问题进行了解答,并强调了方案使用的注意事项,以期望提高我国耐药肺结核的诊治水平。

关键词: 结核,肺, 抗药性, 临床方案, 投药,口服, 总结性报告(主题)

Abstract:

In 2020, the World Health Organization (WHO) proposed the all-oral treatment for drug-resistant pulmonary tuberculosis. Analysis showed that the success rate of all-oral treatment is higher than that of the treatment regimen containing injection. Although WHO guidelines recommend all-oral treatment regimen for different drug-resistant pulmonary tuberculosis patients, some drugs or dosages are not suitable for Chinese patients. There is no consensus on all-oral treatment for drug-resistant pulmonary tuberculosis patients in China. In order to formulate all-oral treatment for drug-resistant pulmonary tuberculosis in China, the Chinese Antituberculosis Association, Beijing Chest Hospital Affiliated to Capital Medical University and the Editorial Board of Chinese Journal of Antituberculosis jointly organized experts to write the “Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition)” (referred to as “Consensus”). Based on the research progress of all-oral treatment for drug-resistant pulmonary tuberculosis at home and abroad in recent years, this consensus recommends suitable all-oral treatment for patients with drug-resistant pulmonary tuberculosis in China, including the types and dosages of drugs used, and the types of patients and their applications and exclusion criteria. In addition, the relevant questions that may be encountered in the treatment are answered, and the precautions for the use of the plan are also emphasized, in order to improve the diagnosis and treatment of drug-resistant pulmonary tuberculosis in China.

Key words: Tuberculosis,pulmonary, Drug resistance, Clinical protocols, Administration,oral, Consensus development conferences as topic